Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

personalized neoantigen DNA vaccine GNOS-PVO2

A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon intradermal delivery by electroporation of GNOS-PVO2, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient-specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:neoantigen vaccine GNOS-PVO2
Code name:GNOS-PVO2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search